

Ariel Miller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/403769/publications.pdf>

Version: 2024-02-01

125
papers

8,308
citations

50276

46
h-index

48315

88
g-index

130
all docs

130
docs citations

130
times ranked

9060
citing authors

#	ARTICLE	IF	CITATIONS
1	Oral Tolerance: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens. <i>Annual Review of Immunology</i> , 1994, 12, 809-837.	21.8	878
2	Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 421-425.	7.1	706
3	Antigen-driven bystander suppression after oral administration of antigens.. <i>Journal of Experimental Medicine</i> , 1991, 174, 791-798.	8.5	436
4	Diagnosis and Classification of 17 Diseases from 1404 Subjects <i>via</i> Pattern Analysis of Exhaled Molecules. <i>ACS Nano</i> , 2017, 11, 112-125.	14.6	386
5	Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. <i>Lancet Neurology</i> , The, 2011, 10, 745-758.	10.2	247
6	Health-related Quality of Life in Multiple Sclerosis: The Impact of Disability, Gender and Employment Status. <i>Quality of Life Research</i> , 2006, 15, 259-271.	3.1	243
7	Revised diagnostic criteria of multiple sclerosis. <i>Autoimmunity Reviews</i> , 2014, 13, 518-524.	5.8	238
8	Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+CD25 ^{hi} LAP+ T cells. <i>Nature Medicine</i> , 2006, 12, 627-635.	30.7	229
9	Treatment of multiple sclerosis with Copolymer-1 (Copaxone [®]): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. <i>Journal of Neuroimmunology</i> , 1998, 92, 113-121.	2.3	226
10	Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. <i>Annals of Neurology</i> , 2006, 59, 780-787.	5.3	183
11	Regulation of Endothelial Matrix Metalloproteinase-2 by Hypoxia/Reoxygenation. <i>Circulation Research</i> , 2002, 90, 784-791.	4.5	157
12	Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseases. <i>Autoimmunity Reviews</i> , 2011, 10, 410-415.	5.8	148
13	Vitamin B12, demyelination, remyelination and repair in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2005, 233, 93-97.	0.6	132
14	Antigen-driven tissue-specific suppression following oral tolerance: Orally administered myelin basic protein suppresses proteolipid protein-induced experimental autoimmune encephalomyelitis in the SJL mouse. <i>European Journal of Immunology</i> , 1994, 24, 2104-2109.	2.9	128
15	Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon β therapy in relapsing and secondary \rightarrow progressive multiple sclerosis patients. <i>Annals of Neurology</i> , 2001, 50, 443-451.	5.3	117
16	Detection of Multiple Sclerosis from Exhaled Breath Using Bilayers of Polycyclic Aromatic Hydrocarbons and Single-Wall Carbon Nanotubes. <i>ACS Chemical Neuroscience</i> , 2011, 2, 687-693.	3.5	113
17	Virtual reality cues for improvement of gait in patients with multiple sclerosis. <i>Neurology</i> , 2006, 66, 178-181.	1.1	111
18	Orally administered myelin basic protein in neonates primes for immune responses and enhances experimental autoimmune encephalomyelitis in adult animals. <i>European Journal of Immunology</i> , 1994, 24, 1026-1032.	2.9	110

#	ARTICLE	IF	CITATIONS
19	Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1077-1088.	2.8	106
20	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016ECTRIMS focused workshop. <i>Multiple Sclerosis Journal</i> , 2018, 24, 590-603.	3.0	101
21	Melatonin dysregulation, sleep disturbances and fatigue in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2012, 314, 37-40.	0.6	98
22	Genetic basis of myasthenia gravis – A comprehensive review. <i>Journal of Autoimmunity</i> , 2014, 52, 146-153.	6.5	98
23	Home-based personalized cognitive training in MS patients: A study of adherence and cognitive performance. <i>NeuroRehabilitation</i> , 2010, 26, 143-153.	1.3	94
24	Sodium intake and multiple sclerosis activity and progression in <scp>BENEFIT</scp>. <i>Annals of Neurology</i> , 2017, 82, 20-29.	5.3	80
25	Hypoxia of endothelial cells leads to MMP-2-dependent survival and death. <i>American Journal of Physiology - Cell Physiology</i> , 2005, 289, C1321-C1331.	4.6	79
26	Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 657-666.	1.5	74
27	Differential effects of proclatic upon activation and differentiation of human B lymphocytes. <i>Journal of Neuroimmunology</i> , 1993, 47, 35-40.	2.3	73
28	Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. <i>BMC Neurology</i> , 2013, 13, 60.	1.8	72
29	Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells. <i>Journal of Neuroimmunology</i> , 2005, 163, 157-164.	2.3	71
30	Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFÎ² in patients with Multiple Sclerosis. <i>Journal of Autoimmunity</i> , 2016, 70, 40-51.	6.5	69
31	Sexual dysfunction in females with multiple sclerosis: quantitative sensory testing. <i>Multiple Sclerosis Journal</i> , 2007, 13, 95-105.	3.0	68
32	Auditory feedback control for improvement of gait in patients with Multiple Sclerosis. <i>Journal of the Neurological Sciences</i> , 2007, 254, 90-94.	0.6	68
33	Soluble tumor necrosis factor receptors reduce bowel ischemia-induced lung permeability and neutrophil sequestration. <i>Critical Care Medicine</i> , 1995, 23, 1377-1381.	0.9	66
34	Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. V. Hierarchy of suppression by myelin basic protein from different species. <i>Journal of Neuroimmunology</i> , 1992, 39, 243-250.	2.3	64
35	Effector and regulatory B cells in Multiple Sclerosis. <i>Clinical Immunology</i> , 2017, 184, 11-25.	3.2	64
36	Immunoregulatory effects of interferon-Î² and interacting cytokines on human vascular endothelial cells implications for multiple sclerosis and other autoimmune diseases. <i>Journal of Neuroimmunology</i> , 1996, 64, 151-161.	2.3	63

#	ARTICLE	IF	CITATIONS
37	Serum anti-Glc(Î±1,4)Glc(Î±) antibodies as a biomarker for relapsing remitting multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2006, 244, 59-68.	0.6	58
38	Integrative analysis of methylome and transcriptome in human blood identifies extensive sex- and immune cell-specific differentially methylated regions. <i>Epigenetics</i> , 2015, 10, 943-957.	2.7	57
39	Impact of exposure to war stress on exacerbations of multiple sclerosis. <i>Annals of Neurology</i> , 2008, 64, 143-148.	5.3	56
40	Internet Usage by Patients with Multiple Sclerosis: Implications to Participatory Medicine and Personalized Healthcare. <i>Multiple Sclerosis International</i> , 2010, 2010, 1-7.	0.8	56
41	Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis. <i>Journal of Neuroimmunology</i> , 2012, 251, 45-54.	2.3	55
42	The ubiquitin proteasome pathway regulates claudin 5 degradation. <i>Journal of Cellular Biochemistry</i> , 2012, 113, 2415-2423.	2.6	55
43	Multiple sclerosis frequency in Israel's diverse populations. <i>Neurology</i> , 2006, 66, 1061-1066.	1.1	53
44	Cathepsins and their endogenous inhibitors cystatins: expression and modulation in multiple sclerosis. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 2421-2429.	3.6	53
45	The influence of vitamin D supplementation on melatonin status in patients with multiple sclerosis. <i>Brain, Behavior, and Immunity</i> , 2013, 32, 180-185.	4.1	51
46	Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein VI. Suppression of adoptively transferred disease and differential effects of oral vs. intravenous tolerization. <i>Journal of Neuroimmunology</i> , 1993, 46, 73-82.	2.3	50
47	A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting. <i>European Journal of Neurology</i> , 2006, 13, 61-71.	3.3	46
48	The role of IL-18 and IL-12 in the modulation of matrix metalloproteinases and their tissue inhibitors in monocytic cells. <i>International Immunology</i> , 2002, 14, 1449-1457.	4.0	45
49	In vitro induction of regulatory T cells by anti-CD3 antibody in humans. <i>Journal of Autoimmunity</i> , 2008, 30, 21-28.	6.5	45
50	Tolerance and suppressor mechanisms in experimental autoimmune encephalomyelitis: implications for immunotherapy of human autoimmune diseases. <i>FASEB Journal</i> , 1991, 5, 2560-2566.	0.5	44
51	Exhaled Breath Markers for Nonimaging and Noninvasive Measures for Detection of Multiple Sclerosis. <i>ACS Chemical Neuroscience</i> , 2017, 8, 2402-2413.	3.5	43
52	New immunosuppressive approaches: Oral administration of CD3-specific antibody to treat autoimmunity. <i>Journal of the Neurological Sciences</i> , 2008, 274, 9-12.	0.6	40
53	Participatory medicine and patient empowerment towards personalized healthcare in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 343-352.	2.8	39
54	Expression of matrix metalloproteinases, sICAM-1 and IL-8 in CSF from children with meningitis. <i>Journal of the Neurological Sciences</i> , 2003, 206, 43-48.	0.6	37

#	ARTICLE	IF	CITATIONS
55	T cells from autoimmune patients display reduced sensitivity to immunoregulation by mesenchymal stem cells: Role of IL-2. <i>Autoimmunity Reviews</i> , 2014, 13, 187-196.	5.8	37
56	The 'Immunological-Synapse' at its APC side in relapsing and secondary-progressive multiple sclerosis: modulation by interferon- β . <i>Journal of Neuroimmunology</i> , 2003, 144, 116-124.	2.3	36
57	Emotional responses of children and adolescents to parents with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005, 11, 464-468.	3.0	36
58	Telemedicine for multiple sclerosis patients: assessment using Health Value Compass. <i>Multiple Sclerosis Journal</i> , 2012, 18, 472-480.	3.0	36
59	Physically Damaged Extracellular Matrix Induces TNF-alpha Secretion by Interacting Resting CD4+ T Cells and Macrophages. <i>Scandinavian Journal of Immunology</i> , 1993, 37, 111-115.	2.7	35
60	Health-related quality of life in multiple sclerosis: psychometric analysis of inventories. <i>Multiple Sclerosis Journal</i> , 2005, 11, 450-458.	3.0	35
61	Cathepsins (S and B) and their inhibitor Cystatin C in immune cells: Modulation by interferon- β and role played in cell migration. <i>Journal of Neuroimmunology</i> , 2011, 232, 200-206.	2.3	35
62	Tight junction proteins expression and modulation in immune cells and multiple sclerosis. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 765-775.	3.6	35
63	Chronotherapy using corticosteroids for multiple sclerosis relapses. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 886-888.	1.9	34
64	Cytokine-mediated modulation of MMPs and TIMPs in multipotential neural precursor cells. <i>Journal of Neuroimmunology</i> , 2006, 175, 12-18.	2.3	33
65	Interferon-Beta Induces Distinct Gene Expression Response Patterns in Human Monocytes versus T cells. <i>PLoS ONE</i> , 2013, 8, e62366.	2.5	33
66	Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses. <i>Frontiers in Immunology</i> , 2022, 13, 868915.	4.8	32
67	Cognitive strategies application of multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2004, 10, 67-73.	3.0	31
68	Bio-markers of disease activity and response to therapy in multiple sclerosis. <i>Clinical Neurology and Neurosurgery</i> , 2004, 106, 249-254.	1.4	31
69	Brain responses to verbal stimuli among multiple sclerosis patients with pseudobulbar affect. <i>Journal of the Neurological Sciences</i> , 2008, 271, 137-147.	0.6	30
70	Antigen-Driven Peripheral Immune Tolerance.. <i>Annals of the New York Academy of Sciences</i> , 1991, 636, 227-232.	3.8	29
71	Translation towards personalized medicine in Multiple Sclerosis. <i>Journal of the Neurological Sciences</i> , 2008, 274, 68-75.	0.6	28
72	Goal disengagement and goal re-engagement among multiple sclerosis patients: Relationship to well-being and illness representation. <i>Psychology and Health</i> , 2009, 24, 175-186.	2.2	28

#	ARTICLE	IF	CITATIONS
73	<scp>VAV</scp>1 and <scp>BAFF</scp>, via <scp>NF</scp>Î [®] B pathway, are genetic risk factors for myasthenia gravis. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 329-339.	3.7	27
74	Modulation of monocytes matrix metalloproteinase-2, MT1-MMP and TIMP-2 by interferon-Î ^³ and -Î ^² : implications to multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2002, 131, 191-200.	2.3	26
75	Emerging therapeutic targets in multiple sclerosis. <i>Current Opinion in Neurology</i> , 2006, 19, 260-266.	3.6	25
76	T lymphocyte adhesion to the fibronectin and laminin components of the extracellular matrix is regulated by the CD4 molecule. <i>European Journal of Immunology</i> , 1992, 22, 7-13.	2.9	24
77	Separation-individuation processes of adolescent children of parents with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2007, 13, 87-94.	3.0	23
78	Methylome and transcriptome profiling in Myasthenia Gravis monozygotic twins. <i>Journal of Autoimmunity</i> , 2017, 82, 62-73.	6.5	23
79	Fingolimod reduces CXCR4-mediated B cell migration and induces regulatory B cells-mediated anti-inflammatory immune repertoire. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 34, 29-37.	2.0	22
80	Opposing effects of the HLA-DRB1*0301-DQB1*0201 haplotype on the risk for multiple sclerosis in diverse Arab populations in Israel. <i>Genes and Immunity</i> , 2010, 11, 423-431.	4.1	21
81	Patients with multiple sclerosis in a war zone: coping strategies associated with reduced risk for relapse. <i>Multiple Sclerosis Journal</i> , 2010, 16, 463-471.	3.0	21
82	Gene Expression Profiling of the Response to Interferon Beta in Epstein-Barr-Transformed and Primary B Cells of Patients with Multiple Sclerosis. <i>PLoS ONE</i> , 2014, 9, e102331.	2.5	21
83	Effect of Fampridine-PR (prolonged released 4-aminopyridine) on the manual functions of patients with Multiple Sclerosis. <i>Journal of the Neurological Sciences</i> , 2016, 360, 102-109.	0.6	21
84	Immunological indicators of disease activity and prognosis in multiple sclerosis. <i>Current Opinion in Neurology</i> , 2002, 15, 233-237.	3.6	20
85	Pseudobulbar affect in multiple sclerosis: Toward the development of innovative therapeutic strategies. <i>Journal of the Neurological Sciences</i> , 2006, 245, 153-159.	0.6	20
86	The Epigenetics of Multiple Sclerosis: Clues to Etiology and a Rationale for Immune Therapy. <i>Annual Review of Neuroscience</i> , 1994, 17, 247-265.	10.7	19
87	Inorganic lead enhances cytokine-induced elevation of matrix metalloproteinase MMP-9 expression in glial cells. <i>Journal of Neuroimmunology</i> , 2002, 132, 123-128.	2.3	17
88	Immunomodulation by chronobiologically-based glucocorticoids treatment for multiple sclerosis relapses. <i>Journal of Neuroimmunology</i> , 2009, 210, 124-127.	2.3	17
89	Cognitive Function of Patients with Crohn's Disease is Associated with Intestinal Disease Activity. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 364-371.	1.9	17
90	Effects of Dextromethorphan/Quinidine on Auditory Event-Related Potentials in Multiple Sclerosis Patients With Pseudobulbar Affect. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 444-452.	1.4	15

#	ARTICLE	IF	CITATIONS
91	Functional Interactions of Fibronectin and TNF α : A Paradigm of Physiological Linkage Between Cytokines and Extracellular Matrix Moieties. <i>Cell Adhesion and Communication</i> , 1994, 2, 269-273.	1.7	15
92	Mediterranean Weather Conditions and Exacerbations of Multiple Sclerosis. <i>Neuroepidemiology</i> , 2010, 35, 142-151.	2.3	14
93	Immunotherapy in autoimmune diseases. <i>Current Opinion in Immunology</i> , 1991, 3, 936-940.	5.5	13
94	Modulation of matrix metalloproteinase-9 (MMP-9) secretion in B lymphopoiesis. <i>International Immunology</i> , 2006, 18, 1355-1362.	4.0	12
95	Shifting paradigms in multiple sclerosis. <i>Current Opinion in Neurology</i> , 2016, 29, 354-361.	3.6	12
96	Pharmacogenetic development of personalized medicine: Multiple sclerosis treatment as a model. <i>Drug News and Perspectives</i> , 2002, 15, 558.	1.5	12
97	Glide-symmetric locomotion reinforcement in patients with multiple sclerosis by visual feedback. <i>Disability and Rehabilitation: Assistive Technology</i> , 2010, 5, 323-326.	2.2	11
98	Multiple sclerosis in diverse populations: characteristics in distinct Arab ethnicities in Israel. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1737-1744.	3.0	11
99	Dimethyl fumarate as a first- vs second-line therapy in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e508.	6.0	11
100	Cimetidine as an immunomodulator in the treatment of herpes zoster. <i>Journal of Neuroimmunology</i> , 1989, 22, 69-76.	2.3	10
101	Genomic profiling of interpopulation diversity guides prioritization of candidate-genes for autoimmunity. <i>Genes and Immunity</i> , 2004, 5, 493-504.	4.1	10
102	Matrix Metalloproteinase-9, Its Tissue Inhibitor(TIMP)-1 and CRP in Alzheimer's Disease. <i>European Neurology</i> , 2005, 53, 155-157.	1.4	10
103	Involvement of phosphodiesterases in autoimmune diseases. <i>Journal of Neuroimmunology</i> , 2010, 220, 43-51.	2.3	10
104	Aberrant expression of the apoptosis-related proteins BAK and MCL1 in T cells in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2012, 244, 51-56.	2.3	10
105	HDL-cholesterol elevation associated with fingolimod and dimethyl fumarate therapies in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731988272.	1.0	10
106	Beliefs about medication as predictors of medication adherence in a prospective cohort study among persons with multiple sclerosis. <i>BMC Neurology</i> , 2021, 21, 136.	1.8	10
107	Dimethyl fumarate promotes B cell-mediated anti-inflammatory cytokine profile in B and T cells, and inhibits immune cell migration in patients with MS. <i>Journal of Neuroimmunology</i> , 2020, 343, 577230.	2.3	9
108	Therapeutic use of dextromethorphan: Key learnings from treatment of pseudobulbar affect. <i>Journal of the Neurological Sciences</i> , 2007, 259, 67-73.	0.6	8

#	ARTICLE	IF	CITATIONS
109	Multiple sclerosis pharmacogenetics: personalized approach towards tailored therapeutics. EPMA Journal, 2010, 1, 317-327.	6.1	8
110	Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis. Current Medical Research and Opinion, 2007, 23, 2823-2832.	1.9	7
111	Mobile phone-based e-diary for assessment and enhancement of medications adherence among patients with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732093930.	1.0	7
112	Multiple modality approach to assess adherence to medications across time in Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2020, 40, 101951.	2.0	7
113	Mobile-phone-based e-diary derived patient reported outcomes: Association with clinical disease activity, psychological status and quality of life of patients with multiple sclerosis. PLoS ONE, 2021, 16, e0250647.	2.5	6
114	Modulation of Human Leukocyte Antigen and Intracellular Adhesion Molecule-1 Surface Expression in Malignant and Nonmalignant Human Thyroid Cells by Cytokines in the Context of Extracellular Matrix. Thyroid, 2000, 10, 945-950.	4.5	5
115	Suppression of Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens. , 1993, , 627-634.		5
116	Multiple sclerosis: from basic immunopathology to immune intervention. Clinical Neurology and Neurosurgery, 2002, 104, 172-176.	1.4	4
117	Concordance Between Persons with Multiple Sclerosis and Treating Physician on Medication Effects and Health Status. Patient Preference and Adherence, 2021, Volume 15, 939-943.	1.8	3
118	Theranostics and Translation toward Personalized Medicine for Multiple Sclerosis. , 2010, , 205-254.		2
119	Personalized Medicine and Theranostics. , 2016, , 387-414.		1
120	198-P: HLA immunogenetics of multiple sclerosis in Israeli arabs. Human Immunology, 2009, 70, S111.	2.4	0
121	ME7 Optimizing Therapeutics for Multiple Sclerosis Patients. Clinical Neurophysiology, 2009, 120, S21.	1.5	0
122	Integrative analysis of DNA methylation and gene expression identifies distinct profiles among immune cells subsets. Journal of Neuroimmunology, 2014, 275, 67-68.	2.3	0
123	The immune-modulatory effects of fingolimod on phenotype and function of B cells from patients with Multiple Sclerosis. Journal of Neuroimmunology, 2014, 275, 214.	2.3	0
124	Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology, 2016, 87, 446-446.	1.1	0
125	Matrix-Metalloproteinases (MMPS) in Astroglial Cells. Advances in Behavioral Biology, 1998, , 149-157.	0.2	0